Onconetix obtains waiver of October payment to Veru; future payment percentage rises to 25%

Onconetix, Inc.

Waives Oct 2024 cash receipt payment due Nov 20, 2024 until Onconetix receives at least $97,000 from Keystone equity line.
In exchange, Onconetix increases Veru's share of net proceeds from future financings/strategic transactions to 25% (from 20%) through June 30, 2025.
Onconetix states it lacks sufficient cash reserves to pay the October Cash Receipt Payments on time.
Amendment executed November 26, 2024; extends forbearance terms under existing April 2024 note agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.